Attenuation of blood-brain barrier dysfunction by functionalized gold nanoparticles against amyloid-β peptide in an Alzheimer's disease-on-a-chip model

Gold nanoparticles (GNP) are highly valuable in nanotechnology due to their biocompatibility and unique physicochemical properties, which make them attractive as nanocarriers for targeted drug delivery. In the context of neurodegenerative diseases (NDDs) such as Alzheimer's disease (AD), GNP hold promise for reducing the toxicity of Amyloid-β peptide (Aβ) aggregates. However, a major challenge in developing new therapies for NDDs lies in the limited reliance on animal models and the difficulty of crossing the blood-brain barrier (BBB). This study investigates the effects of GNP on Aβ toxicity using a human-based BBB-organ-on-a-chip model (BBB-oC), mimicking the 3D cellular architecture of the BBB under both normal and pathological conditions. We rationally designed a novel nanosystem functionalized with the peptide D3, which functions both as a selective Aβ toxicity inhibitor and a BBB-targeting agent. The results show that GNP can cross the BBB, reduce the Aβ-induced cytotoxicity, and promote the maintenance of the BBB integrity. Moreover, controlling the shape of GNP further enhanced their protective effect. Overall, this work highlights the feasibility of rationally designed GNP as a promising therapeutic strategy for AD, evaluated through a more reliable and predictive human-relevant model.

Authors

Institutions

Publication Details

Journal
Materials Today Bio
Published
2025-10-25
DOI
https://doi.org/10.1016/j.mtbio.2025.102453
Citations
1
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
1.16
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Attenuation of blood-brain barrier dysfunction by functionalized gold nanoparticles against amyloid-β peptide in an Alzheimer's disease-on-a-chip model

Rebeca Aldunate, Anna Lagunas, Freddy Célis, Andreas Tapia-Arellano et al.
1 citations
Materials Today Bio
Alzheimer's disease research and treatments
1.16
article

Attenuation of blood-brain barrier dysfunction by functionalized gold nanoparticles against amyloid-β peptide in an Alzheimer's disease-on-a-chip model

Rebeca Aldunate, Anna Lagunas, Freddy Célis, Andreas Tapia-Arellano, Marcelo J. Kogan, Pablo Cabrera-Barona, Amado Cruz Crespo, Josep Samitier, Karen Bolaños, Eyleen Araya, Sujey Palma-Florez, Elizabeth Cortés-Adasme, Michael Matus, Natalia Hassan, Mònica Mir, Melina Pérez, Aurora J. Araya-Vergara
article en
1 citations

Abstract

Gold nanoparticles (GNP) are highly valuable in nanotechnology due to their biocompatibility and unique physicochemical properties, which make them attractive as nanocarriers for targeted drug delivery. In the context of neurodegenerative diseases (NDDs) such as Alzheimer's disease (AD), GNP hold promise for reducing the toxicity of Amyloid-β peptide (Aβ) aggregates. However, a major challenge in developing new therapies for NDDs lies in the limited reliance on animal models and the difficulty of crossing the blood-brain barrier (BBB). This study investigates the effects of GNP on Aβ toxicity using a human-based BBB-organ-on-a-chip model (BBB-oC), mimicking the 3D cellular architecture of the BBB under both normal and pathological conditions. We rationally designed a novel nanosystem functionalized with the peptide D3, which functions both as a selective Aβ toxicity inhibitor and a BBB-targeting agent. The results show that GNP can cross the BBB, reduce the Aβ-induced cytotoxicity, and promote the maintenance of the BBB integrity. Moreover, controlling the shape of GNP further enhanced their protective effect. Overall, this work highlights the feasibility of rationally designed GNP as a promising therapeutic strategy for AD, evaluated through a more reliable and predictive human-relevant model.

Materials Today BioVol. 35
Universidad Andrés Bello (CL), Millennium Science Initiative (CL), Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (ES), Pontificial Catholic University of Valparaiso (CL), Millennium Nucleus of Ion Channel Associated Diseases (CL), Universidad Santo Tomás (CL), Advanced Center for Chronic Diseases (CL), Metropolitan University of Technology (CL), Institute for Bioengineering of Catalonia (ES), University of Chile (CL), Universitat de Barcelona (ES)
Openalex Percentile: Top 17%
Alzheimer's disease research and treatments
1.16
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.